Northwest Biotherapeutics, Inc (NASDAQ:NWBO) Ratings Get Better

814

Dallas, Texas 03/20/2014 (FINANCIALSTRENDS) –  Northwest Biotherapeutics, Inc (NASDAQ:NWBO), a clinical-stage biopharmaceutical company developing immunotherapeutic options for cancer treatment, is bettering its rating from last week to this week. It should be noted that last week the company’s shares dipped drastically after receiving a downgrade from a research firm Oppenheimer. In light of concerns over its valuations, Oppenheimer downgraded Northwest Biotherapeutics’s shares to “perform” from “outperform”.

If you remember, last week the company’s stock rose by as much as 36 percent in wake of special approvals in Germany. Northwest Biotherapeutics announced that Germany has given an approval to sell the company’s brain cancer drug, DCVax-L, in the country. Also, in return, the company will be able to charge full money for the medications, and be reimbursed through sickness funds.

After receiving a special hospital exemption from Germany on its “experimental” drug, Northwest Biotherapeutics surged by a whopping 36 percent. Under the special permission, the company will be able to sell its cancer drug for five years in the country; and would also hold the right to further extend or renew the marketing rights after the term of five years get completed.

It is interesting to note that the final-stage study of DCVax-L is yet to be completed, but Germany’s approval does bring lot of cheer among the company’s investors. The drug is being tested in patients suffering from the most severe form of the disease, known as ‘Glioblastoma multiforme’.

On the other hand, initial data from DCVax-L’s late-stage trial was expected to come last month, but has not yet made available. This has definitely been a reason for concern.

Northwest Biotherapeutics, Inc (NASDAQ:NWBO) is expected to start selling its product in Germany in the next few months; and said it would also increase the production at its Leipzig facility.

Subscribe to get your free report!

* indicates required
*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.